We had big movements in two stocks in the biotech/healthcare space. One was Abbvie (ABBV), whose stock was hammered late in the trading session after it was announced that the California Department. Of Insurance is suing the company over alleged kickbacks in the promotion of Humira. Meanwhile, Viking Therapeutics (VKTX) was up dramatically on successfully meeting endpoints for its phase 2 study of VK2809. Here’s an overview of both stocks and what we’re looking for going forward.
As we start a brand new quarter in 2026, it also resets the earnings cycle for companies to report their quarterly results — and I believe that Q1 Earnings Season could have a lot in store. Q4 earnings season at the start of the year gave traders a lot to process. It also set the […]
Read Article
The March 2026 Jobs Report was among the most anticipated ones in recent memory. Right now, the economy is being shaped by a number of factors: These current circumstances — combined with February’s bad jobs report — had traders preparing for the worst. Fortunately, the March 2026 Jobs Report looked much better than expected…at least […]
Read Article
Written By: Howard Greenberg As everyday traders put their trading plans into action for 2026, penny stocks might not be on many of their radars. It’s totally understandable why penny stocks may not appeal to the more calculated seasoned traders. Their reputations for susceptibility to manipulation, extreme volatility, and low liquidity make them way too […]
Read Article
Equities finished the holiday-shortened week with a more complicated message than the headline indexes suggested. The Dow Jones Industrial Average pushed to new records this week, helped by industrials and financials, while the broader market wrestled with a hawkish Federal Reserve, rising 2-year yields, and an increasingly narrow technology trade. The week’s major geopolitical headline was […]
Read Article
Major indices changed course in a meaningful way this past week, ending in the green despite significant initial volatility. For the week, the S&P 500, Dow and Nasdaq-100 all gained just under 1%. Headline whiplash about developments in the war between the U.S. and Iran ended with hope that an agreement is in the offing. […]
Read Article
SpaceX (SPCX) closed its first day of trading up 19 percent. The biggest IPO in market history is now public, and traders are already asking the same question: What’s next for SPCX? The hype was real, but Charlie Moon believes the more interesting story is just starting to unfold. He recorded a breakdown, with his […]
Read ArticleWe choose to let our members and students speak for themselves. We do not actively solicit testimonials, no compensation has been paid for any testimonial, and testimonials are not necessarily representative of the experience of all students. All monetary claims made in testimonials that you see depicted in our marketing material have been verified by Prosper Trading Academy and attested to by the members that have given them. Verified testimonials encompass “experience” reviews that highlight the personal experiences of working with our team and “performance” testimonials where we verify trading success of students who have enrolled in our programs.Given the broad reach of the internet, testimonials and reviews of our programs that we have not been able to verify can be found on various websites across the internet which are beyond our editorial control. While we do very much enjoy hearing positive things from our students and it is critical to our mission that everyone is satisfied with their journey with Prosper, we encourage you to take both verified and unverified testimonials for what they are.